Replies to post #1888 on Catalyst Pharmaceutical Partners (CPRX)

[ipo_dude]

Kaboom time

Catalyst's Firdapse drug gets breakthrough status
08:22 AM ET · CPRX

Catalyst Pharmaceutical (CPRX +47.2%) has received breakthrough therapy designation from the FDA for its Firdapse drug for treating Lambert-Eaton Myasthenic Syndrome (LEMS), a rare autoimmune disease that can be severely disabling and even life-threatening.
"With no approved or effective symptomatic treatment currently available for LEMS, Firdapse has the potential to be the first-line treatment option for patients with this rare condition," says Catalyst CEO Patrick McEnany.
The primary symptom of LEMS is muscle weakness, which makes walking difficult. Sufferers can also experience problems with swallowing and talking, the drooping of eyelids and facial weakness. (PR)

[ipo_dude]

Kaboom time!!!

Catalyst Pharmaceutical (CPRX +47.2%) has received breakthrough therapy designation from the FDA for its Firdapse drug for treating Lambert-Eaton Myasthenic Syndrome (LEMS), a rare autoimmune disease that can be severely disabling and even life-threatening.